NCT06225843View on ClinicalTrials.gov

Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
BIOLOGICAL

Sotevtamab

Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU)

COMBINATION_PRODUCT

FOLFOX

FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.

Trial Locations (1)

H2X 3E4

RECRUITING

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal

Sponsors
All Listed Sponsors
lead

Alethia Biotherapeutics

INDUSTRY

NCT06225843 - Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis | Biotech Hunter | Biotech Hunter